Polyphenol-Rich Cocoa Powder As Adjuvant Therapy In Patients With Covid-19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202203874034949

Enrollment

126

Registered

2022-03-15

Start date

2022-03-15

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Respiratory

Interventions

Royale cocoa powder

Sugar

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: . Confirmed COVID-19 positivity at admission . Ability to tolerate oral medication and oral food intake

Exclusion criteria

Exclusion criteria: • Patients who are unable to swallow/receive oral medication • Patients requiring ICU care on screening • Pregnant or lactating COVID-19 patients - based on their declaration and pregnancy test results when required. • Self-reported known allergies or intolerance to natural cocoa • Inability or unwillingness to be followed up for the trial period

Design outcomes

Primary

Measure	Time frame
The primary outcomes will be improvement in COVID-19 symptoms and laboratory evidence of decrease in coagulation parameters.	—

Secondary

Measure	Time frame
• Rate of decline of SARS-CoV-2 viral load from baseline and 96 hours later • Duration of hospital admission • Time to clinical recovery • Final clinical prognosis and need for ICU management • Proxy measures of improvement in endothelial function.	—

Countries

Ghana

Contacts

Public ContactLade Wosornu

Ghana Academy of Arts and Sciences

ladewosornu@gmail.com+233274723333

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026